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Abstract
Background: CD8+ T cell responses play an important role in the control of HIV-1. The extensive sequence diversity of HIV-1
represents a critical hurdle to developing an effective HIV-1 vaccine, and it is likely that regional-specific vaccine strains will
be required to overcome the diversity of the different HIV-1 clades distributed world-wide. Unfortunately, little is known
about the CD8+ T cell responses against CRF01_AE, which is responsible for the majority of infections in Southeast Asia.
Methodology/Principal Findings: To identify dominant CD8+ T cell responses recognized in HIV-1 clade CRF01_AE infected
subjects we drew upon data from an immunological screen of 100 HIV-1 clade CRF01_AE infected subjects using IFN-
gamma ELISpot to characterize a novel immunodominant CD8+ T cell response in HIV-1 Gag restricted by HLA-Cw*0102
(p24, 277YSPVSILDI285, YI9). Over 75% of Cw*0102+ve subjects targeted this epitope, representing the strongest response in
more than a third of these individuals. This novel CD8 epitope was located in a highly conserved region of HIV-1 Gag known
to contain immunodominant CD8 epitopes, which are restricted by HLA-B*57 and -B*27 in clade B infection. Nonetheless,
viral escape in this epitope was frequently observed in Cw*0102+ve subjects, suggestive of strong selection pressure being
exerted by this common CD8+ T cell response.
Conclusions/Significance: As HLA-Cw*0102 is frequently expressed in the Thai population (allelic frequency of 16.8%), this
immunodominant Cw*0102-restricted Gag epitope may represent an attractive candidate for vaccines specific to CRF01_AE
and may help facilitate further studies of immunopathogenesis in this understudied HIV-1 clade.
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Introduction
Treatment of HIV-1 infections with antiretroviral therapy has
had an enormous impact on delaying disease progression in HIV-1
infections [1]. Unfortunately, the cost and delivery of these live-
saving drugs remain substantial hurdles to providing access to all
infected individuals, especially those in developing countries which
account for a majority of all cases [2]. Furthermore, drug
resistance and side effects continue to be problematic even though
new antiretroviral treatment agents are being perpetually
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23603developed [3]. Therefore, the design of an effective HIV-1 vaccine
remains a priority.
It is believed that the cellular immune response [4–7], in
addition to neutralizing antibodies, plays a key role in the control
of HIV [8–10]. Their ability to recognize infected cells depends
upon the presentation of viral peptides by host human leukocyte
antigen (HLA) molecules on the surface of the cell. Each HLA
molecule binds a very specific set of 8–12 amino acid peptides, or
epitopes, derived from intracellular viral proteins. The HLA
molecules represent a highly diverse set of proteins, which can vary
considerably between different ethnic populations [11,12].
As a result of the specificity of HLA binding of viral peptides,
HIV-1 is capable of evading many CD8+ T cell responses through
single amino acid mutations in the epitopes [13,14]. It is known
that while some regions of the virus are highly diverse [15], other
regions remain highly conserved due to preservation of critical
functional or structural domains [16–19]. Therefore, there has
been much focus on the identification of strongly and frequently
targeted CD8 epitopes from highly conserved regions of the virus
that would be refractory to viral escape due to high fitness costs.
Although substantial CD8 epitopes restricted by HLA-A and -B
alleles have been identified, to date very few HLA-C-restricted
epitopes have been reported (http://www.hiv.lanl.gov/content/
immunology). As such, the potential of HLA-C restricted
responses may be underappreciated especially given the ability
of HIV-1 Nef to selectively down-regulate HLA-A and -B
restricted CTL responses [9]. As well, single nucleotide polymor-
phisms near the HLA-C gene locus have recently shown to be
associated with a lower HIV viral set point [20]. More specifically,
individuals with a variant 35 kb upstream of the HLA-C loci (-
35C/T) which results in higher –expression of HLA-C alleles,
exhibit enhanced control of viremia as compared to those with low
HLA-C expressing alleles [21]. HLA-C polymorphisms may also
have a direct effect on HIV infectivity and replicative capacity
[22]. As such, further exploration of the role of HLA-C alleles in
HIV infection is warranted.
A major hurdle in the design of an effective HIV-1 vaccine is the
vast inter-clade sequence diversity of HIV-1, compounded by the
numerous distinct clades distributed globally. To contend with this
diversity, it is believed that clade-specific vaccines will be needed
[15]. In Thailand, the predominant strain of HIV-1 is the
circulating recombinant form CRF01_AE, which accounts for
between 90 and 95% of infections [23]. According to UNAIDS,
HIV prevalence in Thailand is estimated at about 1.4% in adults
of 15 to 49 years (0.7–2.1%) (http://www.unaids.org). In addition
to Thailand, CRF01_AE is also prominent in other countries of
Southeast Asia (except India), where it accounts for approximately
84% of all infections [24]. Some studies suggest that HIV-1 clade
CRF01_AE infected individuals show faster progression rates to
AIDS and shorter median survival than individuals from cohorts
located in Eastern and Southern Africa or high-income countries,
but similar to those with clade D infection in Sub-Saharan Africa
[25,26].
To date little is known about the cellular immune response
against CRF01_AE [27–29]. This impairs the identification of
promising epitope dense regions of the virus for inclusion into
vaccines and the study of its pathogenesis. In this report, we have
identified a frequently targeted novel immunodominant CD8
epitope in Gag in HIV-1 clade CRF01_AE infected subjects from
Thailand. This novel epitope is restricted by HLA-Cw*0102, a
frequent HLA-C allele in the Thai population (allelic frequency of
16.8%, http://www.ncbi.nlm.nih.gov). Even though the specified
epitope lies in a highly conserved region of Gag, HIV-1 was found
to frequently escape from this CTL response suggestive of a strong
selection pressure. The identification of frequently targeted
epitopes, especially in conserved regions, will be important in
the design of HIV vaccines.
Results
Identification of a commonly targeted CD8 epitope in
Gag in CRF01_AE infected subjects
To identify commonly targeted CD8+ T cell epitopes in the
Thai population, we drew upon data from an immunological
screen of a cohort of 100 treatment naı ¨ve, HIV-1 clade
CRF01_AE infected subjects (Table 1) using an IFN-c ELISpot
assay and overlapping 18-mer peptides spanning the entire HIV-1
clade CRF01_AE genome (Buranapraditkun et al, manuscript in
preparation). Infection with CRF01_AE was confirmed through
Gag sequencing. One overlapping peptide (OLP-038; 273IVR-
MYSPVSILDIRQGPK290) in Gag was recognized by 29 subjects
(the 7th most frequently targeted OLP), with an average of 1,428.3
SFCs in responders. In 9 (31%) subjects with a detectable response
against OLP-038 this also represented the overall strongest
response.
This epitope is located within an epitope-dense region of p24
which includes epitopes restricted by various HLA alleles including
-A*02, -B*52, and -Cw*18 (http://www.hiv.lanl.gov/content/
immunology). None of these alleles were predominantly expressed
in responders. However, 25 of the 29 subjects (86.2%) mounting
detectable IFN-c T cell responses against OLP-038 expressed
HLA-Cw*0102 (p=8.74*10
213).
Conversely, of the 33 Cw*0102+ve subjects in our cohort, 25
(75.8%) had a detectable response against OLP-038, ranging from
230 to 3,990 SFCs (the mean of SFC in the responders was 1,561)
(Fig. 1) making it the most frequently targeted peptide in the
Cw*0102+ve subjects, vs. 6% recognition (4 subjects) in the
Cw*0102-ve subjects with an average of 598 SFCs.
Definition of the novel Cw*0102-restricted CD8 epitope
p24 277YI9285
To define the restricting HLA allele, we conducted ELISpot and
Chromium-release assays. In the
51Cr-release assay, PBMC from
subject 0578 recognized OLP-038 only when presented by BLCL
from subjects expressing HLA-Cw*0102 (Fig. 2A). We then
conducted fine mapping of the epitope using serial dilutions of
peptide truncations in both IFN-c ELISpot (Fig. 2B) and
51Cr-
release assay (Fig. 2C). These assays established the minimal
optimal epitope as the 9-mer 277YSPVSILDI285 or YI9, although
Table 1. Clinical characteristics of HIV-1 clade CRF01_AE
infected subjects (N=100).
Total Cw*0102+ve Cw*0102-ve
Number of patients 100 33 67
Female 47 15 (45%) 32 (48%)
Male 53 18 (55%) 35 (52%)
Median age 32 31 32
Median sero-diagnosis
(year range)
1.4 (0–14.8) 1.4 (0–7.4) 1.4 (0–14.8)
Median CD4+ T
cells (cells/mm
3)
272 227 284
Median plasma HIV-1
RNA (copies/ml)
23,430 29,778 22,029
doi:10.1371/journal.pone.0023603.t001
A Novel Gag Epitope HLA-C HIV-1 CRF01_AE
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23603Figure 1. Predominant recognition of OLP-038 in Cw*0102+ve subjects. ELISpot responses in Cw0102+ve and Cw0102-ve subjects were
tested. The majority of Cw*0102+ve subjects (25/33; 76 percent) exhibited an ELISpot response against OLP-038, versus a minority of the Cw*0102-ve
subjects (4/67; 6 percent); p,0.0001.
doi:10.1371/journal.pone.0023603.g001
Figure 2. Identification of the novel Cw*0102-restricted CD8 epitope 277YI9285. (A) Autologous BLCL from subject 0578 who strongly responded
to OLP-038, and BLCL targets from 6 other individuals expressing one of subject 0578 HLA alleles, were tested for their ability to recognize peptide-
pulsed targets using a
51Cr-release assay. Responses were only detected in the presence of HLA-Cw*0102, confirming this as the restricting HLA allele.
The optimal CD8 epitope within OLP-038 was then fined mapped using both (B) ELISpot and (C)
51Cr-release assays, identifying the 9-mer YI9 as the
minimal optimal epitope.
doi:10.1371/journal.pone.0023603.g002
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reactive. CD8-restriction of this epitope was also confirmed using
CD4 and CD8 depletions (data not shown).
Frequent viral escape from the OLP-38 epitope in
Cw*0102+ve subjects
To determine whether YI9-restricted CD8 responses were
capable of exerting immune selection pressure upon HIV-1,
sequence data of the Gag-region was generated from all subjects.
As shown in Fig. 3, irrespective of the expression of Cw*0102, 73/
100 (73%) sequences from this cohort were conserved. This is
nearly identical to an analysis of 437 CRF01_AE sequences from
Thailand derived from the LANL HIV Sequence Database, in
which 72% of sequences were conserved. Notably, in the absence
of Cw*0102, the number of consensus sequences increased to 56/
67 (83%), while in contrast we observed a strong association
between mutations in YI9 and the expression of Cw*0102. More
specifically, in Cw*0102+ subjects 16/33 (48%) exhibited
mutations in YI9 versus only 11/67 (16%) in Cw*0102-ve subjects
(p=0.0015). In Cw*0102 subjects with a wildtype sequence at YI9
we detected a response rate of 100% against OLP-038, with an
average ELISpot response of 1,832 SFCs. In contrast, only 50% of
Cw*0102 subjects exhibiting mutations in YI9 mounted detectable
responses against this epitope, and with a lower average
magnitude of 986 SFCs in responders (p,0.001). While mutations
occurred at positions P2, P4 and P5, the most frequent mutation
was a single amino acid substitution at position 4, mutation
V280X (predominantly Threonine). Mutations at P4 reduced the
response rate to 71.4% and diminished the magnitude of the
ELISpot responses to an average of 682 SFCs in responders
(p,0.001). The amino acid mutation at P5, S281G, reduced the
ELISpot response rate to 50%, with an average magnitude of the
ELISpot response of 1,493 SFCs in responders (p,0.001). More
dramatically, mutations at P2, which occurred in four cases,
appeared to completely impair ELISpot responses (p,0.001). No
significant difference in VL or CD4 counts could be found
however between the different groups.
Finally, ELISpot assays using mutated peptides were conducted
on PBMC from two additional Cw*0102-positive patients not
originally included in the primary cohort due to a lack of
sequencing data. In both patients we were able to illustrate a loss
of recognition for both of the peptides with the V280T and S278K
mutation (Fig. 4), illustrating the direct effect of these Cw*0102-
associated mutations on CD8+ T cell recognition. Subsequent
sequencing of these subjects showed a V280A mutation in subject
5043 (not tested), and a wildtype sequence in subject 5070. In
summary, these data define YI9 as an immunodominant and novel
Gag epitope in the Thai population restricted by the common
HLA-Cw*0102 allele.
Discussion
This study identifies a previously unknown HLA-Cw*0102
restricted CD8 epitope 277YSPVSILDI285 (YI9) located in p24
Gag. Although the overlapping peptide OLP-38 containing YI9
was only the 7
th most frequently targeted epitope in this cohort
(Buranapraditkun et al, manuscript in preparation), it exhibited
the clearest HLA restriction of all dominantly targeted OLPs.
Indeed, over 86% of subjects with detectable ELISpot responses
against OLP-38 expressed Cw*0102.
Despite the location of the YI9 epitope in a highly conserved
region of p24 Gag, mutations in YI9 were frequently observed in
this epitope in nearly 50% of all Cw*0102+ve subjects. The most
frequently occurring mutation was a V280T mutation at position 4
(18% of all Cw*0102+ve subjects), which was all but absent in
Cw*0102-ve subjects. The frequency of Cw*0102 in the Thai
population, and the frequent escape observed in this epitope,
suggests the likely reversion of this escape mutation back to
wildtype upon transmission to a new host. These data may suggest
the ability of this mutation to impair viral replication as observed
for other escape mutations in this region of p24 [30,31]. Position 2
represents an anchor position for binding of the peptide to the
HLA class I groove, and thus a potentially more promising
pathway to viral escape. Here, mutations at position 2 were
present in 12% of all Cw*0102+ve subjects and again rarely in
Cw*0102-ve subjects.
The frequent recognition of the YI9 epitope (76%) observed in
this cohort suggests it to be amongst the most immunodominant in
CRF01_AE infections. In comparison to extensive immunodomi-
nance data available for clade B infection [32], only a handful of
CD8 epitopes are as commonly targeted as YI9 in acute or chronic
infection [33]. Notably, this peptide maps close to the region of
Gag containing immunodominant CD8 epitopes restricted by
HLA-B*27 (263KRWIILGLNK272) and HLA-B*57 (240TSTLQE-
QIGW249). Both of these HLA alleles are associated with a
Figure 3. Cw*0102 associated footprints in the YI9 epitope. Gag sequences were generated from all 100 subjects and sequence variation
within the YI9 epitope compared between Cw*0102+ve and Cw*0102-ve subjects. Mutations in YI9 were significantly elevated in subjects expressing
Cw*0102 (p=0.001), with the V280X and S281G mutations predominating.
doi:10.1371/journal.pone.0023603.g003
A Novel Gag Epitope HLA-C HIV-1 CRF01_AE
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23603beneficial outcome in clade B infections [17,32,34–36]. However,
in our cohort there is no significant difference in viral loads
between Cw*0102+ve and Cw*0102-ve patients (mean 71,184.5
vs. 69,732.2 copies/ml, p=0.89), nor in CD4 T cell counts (mean
243.6 vs. 292.6 cells/mm
3, p=0.278). This may be the result of
the high rate of viral escape within this epitope [37].
Further analysis of the HLA data showed linkage disequilibrium
between Cw*0102 with B*4601 (p=8.55*10
213), another com-
mon HLA epitope in the Thai population (allelic frequency
17.2%, NCBI). While we saw significantly more mutations in YI9
in Cw*0102+ve subjects than in Cw*0102-ve subjects (p=0.0015),
there was no significant difference in the occurrence of YI9
mutations in B4601+ve versus B4601-ve patients (p=0.197).
Thus, this argues against B4601 as the restricting HLA type, as
does the strong data showing restriction of this response in
Cw*0102 positive cells (Fig. 2A).
HIV is known to down-regulate HLA-A and HLA-B alleles on
the cell surface [38], leaving HLA-C intact in order to protect cells
from attack by NK cells [39]. As such, HLA-A or HLA-B
restricted CD8+ T cells may be partially compromised in their
ability to recognize and destroy HIV-infected cells as compared to
HLA-C restricted responses. However, few HLA-C restricted
epitopes have been identified to date (http://www.hiv.lanl.gov/
content/immunology/tables/ctl_summary.html). As such, a great-
er focus on the identification and characterization of HLA-C
restricted responses may be warranted to aid in the development
of an effective HIV vaccine.
Inactivated virus and protein-based vaccines have not been
able to induce sufficient antibody responses that lead to
immune control in HIV-1 infection [40–42]. Although to date
all attempts to induce CD8+ T cell responses against HIV-1
that reduce viral load set point or even prevent infection have
failed [43], recent results have demonstrated the importance of
those responses for controlling HIV-1 responses [44]. Thus, it
is important to identify immunodominant epitopes in HIV-1
that are commonly targeted. Given that an effective HIV
vaccine will likely have to be clade specific [15], there are very
few data on CD8 epitopes in clade CRF01_AE which is the
dominant clade in Southeast Asia [45]. Therefore, increased
knowledge of immunodominant CD8 epitopes and their
correlation with viral control in CRF01_AE infection is
warranted to shed more light upon T-cell based HIV vaccine
developments in this region.
Materials and Methods
Ethics Statement
This study was approved by the Faculty of Medicine,
Chulalongkorn University’s Institutional Review Board (IRB)
and the IRB at the Massachusetts General Hospital and all study
subjects provided written informed consent.
Subjects
100 HIV-1 clade CRF01_AE (as obtained by Gag sequence)
infected Thai volunteers were enrolled at The Immune Clinic,
The King Chulalongkorn Memorial Hospital and Anonymous
Clinic, Thai Red Cross AIDS Research Centre in Bangkok,
Thailand. Viral load, HLA type, Gag sequences and ELISpot data
were collected from each of the individuals. All subjects were
antiretroviral treatment naı ¨ve, with a suspected seroconversion
between 1992 and 2007. CD4+ T cell counts ranged from 1 to 906
cells/mm
3 (mean 294 cells/mm
3), plasma HIV-RNA levels ranged
from 162 to 1,040,830 copies/ml (mean 74,693 copies/ml), as
determined by the Chiron b-DNA Monitor test (Quantiplex v3.0,
Bayer). Plasma HIV-RNA levels greater than 500,000 copies/ml
were tested by the Abbott Real Time PCR HIV-1 Assay (range
40–10,000,000). Clinical data are summarized in Table 1.
HLA Typing
High resolution HLA Class I typing was performed by DNA
Sequenced Based Typing (SBT) at The University of Oklahoma
Health Sciences Center CLIA/ASHI certified high resolution
HLA tying laboratory. Briefly, exons 2 and 3 of class I gene were
amplified and DNA sequenced. Ambiguous types were resolved to
4 digits with either group specific amplification followed by DNA
sequencing of the specifically amplified allele and/or by PEL-
FREEZ/Invitrogen UNITRAY SSP kits.
PBMC Isolation and BLCL preparation
Peripheral blood mononuclear cells (PBMC) were isolated by
density gradient separation with Isoprep (Robbins Scientific
Corporation, Sunnyvate, CA) and cryopreserved for further
immunological assays. Briefly, after removal of plasma, ACD-
treated whole blood was diluted 1:1 with RPMI1640 medium
containing 2 mM L-Glutamine (Gibco, USA) and layered over
Isoprep. Samples were then centrifuged at 1,500 rpm for 30 min
and the PBMC layer harvested and washed twice with RPMI1640.
Figure 4. Cw*0102-associated mutations in YI9 impair CD8+ T cell recognition. BLCL from Cw*0102+ve subjects 5043 and 5070 were
pulsed with serial dilutions of wildtype and variant forms of YI9 and tested for recognition by ELISpot assay. P2 mutation S278K, P4 mutation V280T,
and P5 mutation S281G all impaired recognition, with the P2 anchor mutation S278K exhibiting consistently the most significant impairment.
doi:10.1371/journal.pone.0023603.g004
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(RPMI1640 supplemented with 100 U/ml of penicillin, 100 U/ml
of streptomycin and 10% heat-inactivated fetal bovine serum
[FBS, Bio Whittaker, Maryland, USA]). Epstein-Barr virus (EBV)-
transformed B-lymphoblastoid cell lines (BLCL) were established
from PBMC of each subject by incubation with supernatant of
EBV for 1 hour at 37uC in 5%CO2. BLCL were maintained in
R20 medium with 1 mg/ml cyclosporin A. The B95-8 cell line was
kindly provided by The National Institute of Health (NIH)
Thailand.
Peptides
Based on sequences of HIV-1 CRF01_AE, available at the HIV
immunology database (http://www.hiv.lanl.gov), a set of 413
overlapping peptides (OLPs) was generated. The peptides were 18-
mers, overlapping by 10 amino acids and spanning the entire
coding region of CRF01_AE. They were synthesized on an
automated peptide synthesizer at the peptide synthesis facility of
the Massachusetts General Hospital using 9-fluorenylmethylox-
ycarbonyl chemistry or were obtained from Research Genetics,
Huntsville, Ala. The novel epitope, peptide YSPVSILDI (YI9),
restricted by HLA-Cw*0102, was synthesized by f-moc chemistry
and provided by Prof. Sarah Rowland-Jones, Weatherall Institute
of Molecular Medicine, John Radcliffe Hospital, Oxford, UK.
Generation of CTL lines by in vitro stimulation
10610
6 PBMC were cultured with peptide at 10 mg/ml for 1 h,
washed, and placed in 24-well plates at 5610
6 cells/ml in R10
containing 330 U/ml of IL-7 (Genzyme). On days 3, 7 and 10,
100 U/ml of IL-2 (kindly provided by NIH, USA) was added to
cultures and CTL activity assessed on day 14.
ELISpot assays
96-well ELISpot plates (MAIP S45; Millipore, Bedford, Mass.)
were coated with 100 ml/well of 2 mg/ml of mouse anti-human
interferon-gamma (IFN-c) monoclonal antibody (mAb) 1-D1k
(Mabtech, Stockholm, Sweden) in PBS and incubated at 37uCi n
5% CO2 for 3 h. The plates were then washed six times with
200 ml PBS/well and blocked with 200 ml R10/well for 1 h at
room temperature. PBMCs were added to the plates at 100,000
cells/well and peptides added at a final concentration of 2 mg/ml.
Culture medium alone served as a negative and PHA-P at final
concentration of 10 mg/ml as a positive control. After incubation
for 16 h at 37uCi n5 %C O 2, the plates were washed manually 6
times with 200 ml/well of PBS/0.05% Tween and once with
200 ml/well of PBS. 50 ml/well of 1 mg/ml mouse anti-human
IFN-c-biotinylated mAb 7-B6-1 (Mabtech, Stockholm, Sweden) in
PBS was added and the plates were incubated for an additional
3 h at room temperature. The plates were again washed and
50 ml/well of streptavidin alkaline phosphatase (Mabtech, Stock-
holm, Sweden) diluted 1:1,000 in PBS was added for 1 h at room
temperature. After washing again, the spots were visualized by
adding 100 ml/well of substrate, 5-bromo-4-chloro-3-indolylpho-
sphate and nitro blue tetrazolium (BIORAD) for 5 min. The
number of specific IFN-c secreting T-cells was counted using an
automated ELISpot reader (Carl Zeiss, Germany). Calculation
was done by subtracting the average negative control value and
expressed as spot forming cells (SFC) per 10
6 input cells. A
response was considered positive if it was greater than (a) 36the
mean background, (b) the mean background +3 standard
deviations or (c) 50 SFC per 10
6 input cells, whichever was
higher. CD8+ T-cell dependence of the optimal YI9 response was
confirmed by CD8 depletion.
Cytotoxicity assays
5610
5 autologous BLCL were pre-incubated with peptides for
1 h and later labeled with 80 mCi of Na2(
51CrO4) (New England
Nuclear, North Billeicas, Mass.) for 1 h. After incubation, the
cells were washed three times with RPMI 1640 medium. The
ratios of effector to target (E:T) cells were 30:1 and 15:1.
Cytolytic activity was determined in a standard 4 h
51Cr-release
assay using U-bottomed microtiter plates containing 5610
3
targets per well. Assays were done in triplicate. For maximum
(max) release, 5% triton-X 100 (TX 100; Sigma) was added to the
target cells.
51Cr release from wells with culture media R10 only
was used to calculate the spontaneous release (min). One hundred
microliters of supernatant were counted on a gamma counter
(Wallac, Gaithersburg, MD). Results were reported in counts per
minute (CPM). Percent lysis was determined by the following
formula: % specific lysis=[(mean CPM Test2mean CPM
spontaneous)/(mean CPM Test2mean CPM Max)]6100. Spon-
taneous release values were less than 30% of maximal release for
all reported assays. For the peptide titration assays target cells
were pulsed with serial 10-fold dilution, starting from a peptide
concentration of 100 mg/ml down to 1 pg/ml (24t o212 log
molar).
HLA-restriction and fine mapping
HLA restriction was performed using autologous or partially
HLA-matched target cells pulsed with peptide in a
51Cr-release
assay. Cells without any added peptide served as negative controls.
Fine mapping of the optimal epitope was performed using
truncations and extensions of the predicted optimal epitope using
both ELISpot and
51Cr-release assay.
51Cr-release assays were
performed at effector to target cell ratios of 30:1 and 15:1.
Sequencing
Autologous virus was sequenced from plasma RNA using
population sequencing as described previously [46]. HIV-RNA
was extracted from plasma using QIAmp RNA Viral Mini kit
(QIAGEN,Germany)and nested PCR wasperformedusingprimers
specific for clades B and CRF01_AE. For the first round of PCR
amplification of Gag a combination of three primer pairs were used:
276F-GAGGTGCACACAGCAAGAGGCG with 1972-R CCCC-
CTATCATTTTTGGTT-TCC, 623F-AAATCTCTAGCAGTG-
GCGCCCGAACAG with 2827R-TAACCCT-GCGGGATGT-
GGTATTCC and 737F-GCGRCTGGTGAGTACGCC with
2110R-RGGAAGGCCAGATYTTCC. Second round nested am-
plification was conducted using the primer pair 294F-GGCGA-
GAGCGGCGACTGGTGAG with 1920R-CTGTAT-CATCTG-
CTCCTGTATC. First round PCR cycling conditions were as
follows: 95uC for 15 minutes followed by 35 cycles of 30 s at 94uC,
30 s at 54uC, 2.25 min at 72uC and a final extension of 68uCf o r
20 min. Nested PCR reactions were 95uC for 2 minutes followed by
35 cycles of 30 s at 94uC, 30 s at 58uC, 1.75 min at 72uCa n daf i n a l
extension of 68uC for 20 min. PCR fragments were then sequenced
bi-directionally on an ABI 3130 automated sequencer using
previously published primers [47]. Sequencher (Gene Codes Corp.,
Ann Arbor, MI) and MacVector 4.1 (Oxford Molecular) were used
to edit and align the sequences. Sequences are submitted under
Genbank numbers HM627654-HM627753.
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